September 24-26, 2024 | Boston, MA

www.targeted-radiopharma-supplychain-manufacturing.com

REGISTER BY SEPTEMBER 24 TO SAVE UP TO $100

WELCOME | EXPERT SPEAKERS | AGENDA | PARTNER WITH US | REGISTER YOUR PLACE

2nd Annual

Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit

Accelerating Your Radiopharmaceutical Production and Supply Capabilities

Advance Radiopharmaceutical Manufacturing Expertise, Expand Access to Isotope Supply & Streamline Your Logistics Network to Deliver Quality Products to Patients on Time Every Time

Expert Speakers Include:

Matthias Friebe
Chief Technology Officer
Ratio Therapeutics

Gokhan Cakmak
Vice President, Supply Chain & Logistics
Fusion Pharmaceuticals

Michael Van Dam
Professor
University of California, Los Angeles

Michelle Hickey
Senior Vice President, Global Manufacturing & Supply
Telix Pharmaceuticals

Erwin Bachmohr
Head of Procurement & Supply Chain
Ariceum Therapeutics

Aruna Korde
Radiopharmaceutical Scientist
International Atomic Energy Agency

Proud to Partner With:

CRB | CAI | PharmaLogic Take The Lead | SHINE | NorthStar Medical Radioisotopes, LLC | RLS Radioisotope Life Sciences

+1 617 455 4188 info@hansonwade.com

targeted-radiopharma-supplychain-manufacturing.com Targeted Radiopharmaceuticals

hansonwade

Welcome to the 2nd Targeted Radiopharmaceutical Supply Chain & Manufacturing Summit

2nd Annual Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit

September 24-26, 2024 | Boston, MA

Accelerating Your Radiopharmaceutical Production & Supply Capabilities

With a resurgence of radiopharmaceuticals in the oncology field – big pharmaceuticals are building their TRP portfolios, with major moves including **Novartis** acquiring **Mariana Oncology** ($1B), **Eli Lilly** collaboration with **Aktis Oncology** ($1.1B) and the monumental multi-billion dollar deals from AstraZeneca, BMS and Eli Lilly earlier this year. With investment in the TRP space having never been higher, don't let your supply chain and manufacturing teams hold back your innovation!

The **2nd Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit** is returning as the only summit dedicated to advancing radiopharmaceutical production to provide a consistent supply of products, accelerating your trials and allowing you to focus on innovation.

Incorporating insights from the leading radiopharmaceutical CMC, regulatory, QC and supply chain experts from **Bayer**, **Novartis**, **POINT Biopharma**, **Telix Pharmaceuticals** and many more, this is your unique opportunity to have confidence in your technical and logistical production. Covering topics such as **isotope production**, **radiolabelling**, **quality control**, **regulatory** considerations and supply networks from transport, temperature control and live tracking, guarantee nothing interrupts your clinical trial from moving forward.

We have already seen **BMS-RayzeBio halt their phase III clinical trial** because of actinium scarcity, highlighting the detrimental impact low production capabilities can cause. Are you assured that your current strategies possess the resilience required to avoid such disruptions?

Don't get caught out, join a community of **80+ radiopharmaceutical manufacturing and supply chain experts** this September, to uncover practical industry insights to advance your manufacturing expertize, and deliver quality products to patients, on time, every time.

What Previous Attendees Have Said:

"I really found this specialized topic summit to be enriching for my duties in logistics. This truly felt like an industry call-to-action workshop to help each other tackle the almost inevitable challenges of radiopharmaceutical transport and handling."

Cellectar Biosciences

"Interesting perspectives, very engaging talks, and lots of practical AI experiences presented, highly technical-driven."

University of California, Los Angeles

Join the 2nd Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit to:

Uncover how the field is tackling pressing radioisotope supply across alpha and beta emitting isotopes including **novel production** processes and generator technologies to determine future isotope viability and security with **Telix Pharmaceuticals**, **Columbia University** and **Clarity Pharmaceuticals**



Streamline your radio pharmaceutical production capabilities by hearing from industry case studies around production **tech transfer**, novel **high yield** approaches and optimal chelator selection while maintaining product quality with **Washington University St. Louis**, **Region Ostergotland** and **Ratio Therapeutics**

Gain global regulatory clarity through understanding supply chain logistical **guidelines**, **licencing** and **equipment requirements** to set your trial up for guaranteed success with **IAEA**, **UCLA** and **Convergent Therapeutics**

Strengthen your supply chain networks and learn from commercial leaders on **courier** and **shipment** selection, optimizing **packaging**, **temperature control**, **live tracking** and **documentation** management with **Fusion Pharmaceuticals** and **Ariceum Therapeutics**

Connect with the technical leaders driving the field to understand exactly what is needed from your commercial collaborations and therefore driving the clinical success of your radio pharmaceuticals with **Brookline Capital Markets** and **Molecular Targeting Technologies**

+1 617 455 4188 info@hansonwade.com
targeted-radiopharma-supplychain-manufacturing.com Targeted Radiopharmaceuticals
hansonwade

Your Expert Speakers

Aruna Korde
Radiopharmaceutical Scientist
International Atomic Energy Agency

Brett Miller
Senior Director, Global Supply Chain
Telix Pharmaceuticals

Chris Pak
President & CEO
Molecular Targeting Technologies

Daniel Thorek
Associate Professor
Washington University in St. Louis

Dawn Spiller
Senior Director of CMC Regulatory Affairs
Astrazeneca

Erwin Bachmohr
Head of Procurement & Supply Chain
Ariceum Therapeutics

Gokhan Cakmak
Vice President, Supply Chain & Logistics
Fusion Pharmaceuticals

Kemp Dolliver
Director of Research
Brookline Capital Markets

Ken Baker
Senior Director External Manufacturing
Fusion Pharmaceuticals

Matthias Friebe
Chief Technology Officer
Ratio Therapeutics

Michael Van Dam
Professor
University of California, Los Angeles

Michelle Hickey
Senior Vice President, Global Manufacturing & Supply
Telix Pharmaceuticals

Shankar Vallabhjosula
Vice President, Radiopharmaceutical Science
Convergent Therapeutics

Angel Colina
Director of Cyclotron Engineering
Columbia University

Bryce Kanter
Senior Director, Commercial Development
Clarity Pharmaceuticals

Jarrod Longcor
Chief Operating Officer
Cellectar Biosciences

Matthew Hadden
Director of Health Physics
RayzeBio

Brandon Buckway
Director of Cyclotron Operations
Huntsman Cancer Institute

Melaku Arega
Associate
Bain Capital Life Sciences

D. Christian Parr
Vice President, Radiochemistry & Technical Operations
PharmaLogic

Pre-Conference Workshop Day
Tuesday, September 24, 2024

Isotope Supply & Manufacturing

8.00-11.00

Workshop A: Evaluating the Commercial & Pharmaceutical Viability of Radioisotopes to Benchmark Potential

This workshop will focus on assessing the commercial and pharmaceutical viability of new isotopes in radiopharmaceutical production. Participants will explore the challenges and strategies for bringing isotopes actinium-225, lutetium-177, lead-212 and copper-67 to market.

This workshop will cover:

- **Assessing Market Demand and Commercial Viability:** Examine the market demand for new isotopes by analyzing therapeutic potential, competitive landscape, and pricing strategies. Discuss the projected market size, patient demographics, and revenue opportunities for isotopes like copper-67, actinium-225, and lutetium-177.
- **Navigating Radiopharmaceutical Development Challenges:** Explore the pharmaceutical challenges in developing new isotopes and radiopharmaceuticals, including production scalability, quality control, and regulatory compliance. Discuss the technical and logistical hurdles in bringing these radiopharmaceuticals from research to clinical application, ensuring they meet GMP standards.
- **Strategic Partnerships and Investment Opportunities:** Identify key strategic partnerships and investment opportunities that can support the development and commercialization of new isotopes. Discuss the role of venture capital, corporate investments, and licensing agreements in overcoming financial and operational barriers.

Chris Pak
President & CEO
Molecular Targeting Technologies

Kemp Dolliver
Director of Research
Brookline Capital Markets

Melaku Arega
Associate
Bain Capital Life Sciences

Post-production Supply Chain Logistic Networks

12.00- 3.00pm

Workshop B: Streamlining Back-End Operations in Radiopharmaceutical Supply Chains to Accelerate Transport

This workshop will focus on enhancing back-end operations within the radiopharmaceutical supply chain, emphasizing processes that support compliance, efficient delivery, and overall logistics. Participants will learn how to integrate back-end operations with front-end logistics and ensure a seamless distribution process.

This workshop will cover:

- **Handling Reimbursements and Payment Processing:** Discuss challenges in billing and payment processing, especially when working with insurers, health systems, and global distribution networks. Review strategies to ensure accurate reimbursement.
- **Managing Inventory and Demand Forecasting:** Explore methods to optimize inventory management based on precise demand forecasting. Identify ways to maintain an on-time supply while avoiding stock shortages or wastage.
- **Compliance in Multi-Product Distribution Networks:** Review how to maintain compliance in multi-product supply chains. Address best practices for managing inventory across multiple facilities, regions, and distribution channels while maintaining compliance.

Pre-Conference Workshop Day
Tuesday, September 24, 2024

Isotope Supply & Manufacturing

3.30-6.30pm

Workshop C: Transforming Facilities to Meet GMP Standards: Regulatory & Operational Challenges

This workshop panel will deep dive into the complexities of retrofitting existing facilities to achieve GMP compliance for radiopharmaceutical production. Participants will delve into the regulatory requirements, operational challenges, and strategic considerations necessary for successful facility transformation.

This workshop will cover:

- **Understanding GMP Regulatory Requirements for Retrofitting:** Discuss the specific regulatory standards that facilities must meet to achieve GMP compliance, focusing on the unique challenges posed by radiopharmaceutical production. Explore how these regulations impact the design and operational workflows of retrofitted facilities.
- **Addressing Operational Challenges in Retrofitting:** Examine the operational difficulties associated with retrofitting existing facilities, such as integrating new technologies, managing contamination risks, and ensuring continuous production during renovations. Identify best practices for minimizing disruptions and maintaining quality control throughout the retrofitting process.
- **Strategic Considerations and Case Studies:** Review case studies of successful facility retrofitting projects by highlighting the strategies used to overcome regulatory and operational challenges and discussing the financial implications, including cost-benefit analysis, and the role of strategic planning in ensuring long-term compliance and operational efficiency.

Shankar Vallabhjosula
Vice President, Radiopharmaceutical Science
Convergent Therapeutics

Brandon Buckway
Director of Cyclotron Operations
Huntsman Cancer Institute

"Very well-run event, much appreciated. The agenda and session speakers were great as well - appropriate topics for the industry."

SHINE Medical Technologies

"The collection of companies (both vendors and drug/diagnostic developers) was great and provided both excellent networking and informative dialogue in the sessions"

Cellectar Biosciences

Conference Day One
Wednesday, September 25, 2024

8.00 Coffee & Check In

Brett Miller
Senior Director, Global Supply Chain
Telix Pharmaceuticals

9.00 **Chair's Opening Remarks**

Strategies for Addressing Isotope Supply Bottlenecks to Ensure Scalability & Stability

Brett Miller
Senior Director, Global Supply Chain
Telix Pharmaceuticals

9.15 **Strategies to Mitigate Isotope Supply Challenges for Actinium & Lutetium to Ensure Consistent Supply**

- Explore scalable production techniques to enhance the availability of key isotopes
- Discuss the sourcing of purified starting materials to reduce contamination and ensure quality
- Review the impact of regulatory hurdles on the supply chain and strategies for compliance

Angel Colina
Director of Cyclotron Engineering
Columbia University

9.45 **Advancements in Generator Technologies for Sustainable Radiopharmaceutical Supply**

- Discuss the latest advancements in generator technologies that facilitate the on-site production of radioisotopes, enhancing accessibility and efficiency
- Explore how these innovative generator systems can streamline the supply chain, reducing the need for frequent and complex logistics associated with isotope transport
- Examine how novel generators contribute to more sustainable practices in radiopharmaceutical production, potentially lowering costs and reducing environmental impact

Matthew Hadden
Director of Health Physics
RayzeBio

10.15 **Advancements in Contamination Control and Scalable Radioisotope Production Processes**

- Identify the latest technological innovations that allow for scalable isotope production while reducing contamination.
- Develop a strong radiation safety program and presence in isotope production.
- Discuss case studies on successful implementations of contamination control measures in isotope production.

10.45 Morning Refreshments & Speed Networking

Improving Isotope Production Capacity Through Technological Innovation

11.45 **Session Reserved For:**

Daniel Thorek
Associate Professor
Washington University, St. Louis

12.15 **Enhancing Radiopharmaceutical Production Through Chelator Selection**

- Discuss how selecting the right chelator enhances manufacturing efficiency and product stability
- Review considerations for scaling up production, focusing on chelator compatibility and cost-effectiveness
- Explore the regulatory implications of chelator choices and strategies for compliance in commercial production

Chris Pak
President & CEO
Molecular Targeting Technologies

12.45 **Reducing isotope demand with an innovative TRP delivery platform**

- Common challenges of short-lived, rapidly clearing TRP. Strategies to overcome these challenges while maintaining product integrity and compliance with regulatory standards
- Evans Blue modification significantly improves pharmacokinetics of targeted peptide radiotherapeutics reducing required dose by >50%
- Lowering isotope use while maintaining efficacy and safety, improves costs, logistics and health economics, potentially expanding the market

Conference Day One
Wednesday, September 25, 2024

1.15 **Lunch & Networking**

Addressing Manufacturing Capacity, Quality & Efficiency Hurdles in Radiopharmaceutical Manufacturing to Achieve Quality Drug Product

Aruna Korde
Radiopharmaceutical Scientist
International Atomic Energy Agency

2.15 **Managing Radioactive Waste in Radiopharmaceutical Manufacturing to Meet Regional Standards**

- Review regional differences in radioactive waste management regulations and how they affect facility compliance
- Develop best practices for handling, storing, and disposing of radioactive waste in line with regional guidelines
- Explore strategies to integrate waste management into the manufacturing process to minimize environmental impact

Matthias Friebe
Chief Technology Officer
Ratio Therapeutics

2.45 **Overcoming Manufacturing Bottlenecks & Maintaining Quality in Radiopharmaceutical Production**

- Examine the shortage of manufacturing facilities and specialized equipment like hot cells
- Identify quality control challenges in multi-product facilities and strategies for maintaining GMP compliance
- Explore effective approaches to streamline production timelines while ensuring adherence to health and radiation safety regulations

3.15 **Afternoon Refreshments**

Understanding Regional & Logistical Complexities in Radiopharmaceutical Manufacturing Across Production Landscape

Jarrod Longcor
Chief Operating Officer
Cellectar Biosciences

3.45 **Integrating Supply Chain Planning and Tracking Strategies to Ensure Consistent Patient Delivery**

- Investigate how to optimize the supply chain to meet clinical demand and maintain a just-in-time inventory to minimize wastage.
- Review supply chain forecasting and coordination with clinical sites to improve the availability of radiopharmaceuticals.
- Explore tracking technologies to ensure accurate dosage delivery and maintain high patient safety standards.

4.15 **Roundtable Discussion: Overcoming Global cGMP Regulatory Hurdles for Efficient Market Access**

Explore the regulatory differences affecting manufacturing and supply chain across regions, particularly in Europe and the U.S

Discuss strategies to harmonize compliance practices for providing clinical supply

Dawn Spiller, Senior Director of CMC Regulatory Affairs, **Astrazeneca**

Identify partnerships with regulatory experts to better navigate international approval processes for faster market entry

Brett Miller
Senior Director, Global Supply Chain
Telix Pharmaceuticals

5.00 **Chair's Closing Remarks**

5.15 **End of Conference Day One**

Conference Day Two
Thursday, September 26, 2024

8.30 **Coffee & Check In**

Brett Miller
Senior Director, Global Supply Chain
Telix Pharmaceuticals

9.00 **Chair's Opening Remarks**

Scaling Radiopharmaceutical Production Through Improved Training, Tech Transfer, Safety & Regulatory Compliance to Meet More Demand

Ken Baker
Senior Director, External Manufacturing
Fusion Pharmaceuticals

9.15 **Enhancing Radiopharmaceutical Production Through Effective Tech Transfer**

- Discuss the critical steps involved in transferring technology from R&D to production scale, emphasizing pre-process validation to ensure consistency and quality
- Explore real-world examples where tech transfer has been pivotal in scaling up production of radiopharmaceuticals. Analyze challenges and solutions encountered during these transitions
- Review key strategies for a smooth tech transfer in radiopharmaceutical production, including collaboration with CDMOs, rigorous process validation, and maintaining regulatory compliance

Prab Takhar
Radiochemist
Region Ostergotland

9.45 **Addressing Shortfalls in Radiopharmaceutical Production Capacity & Equipment to Improve Production Efficiency**

- Discuss the shortage of specialized equipment, such as hot cells, and identify strategies to enhance production capacity through vendor partnerships
- Investigate approaches to balance existing manufacturing facilities' capacity with increasing clinical and commercial demands
- Explore partnerships and internal production strategies to alleviate equipment supply chain issues

Michael Van Dam
Professor
University of California, Los Angeles

10.15 **Enhancing Radiopharmaceutical Safety & Quality Through Radiolabeling**

- Explore the latest techniques in radiolabeling that enhance the specificity and stability of radiopharmaceuticals
- Discuss how radiolabeling contributes to stringent quality control measures, ensuring that radiopharmaceuticals meet safety standards
- Review the impact of precise radiolabeling on improving the safety profiles of radiopharmaceuticals and complying with regulatory frameworks

10.45 **Morning Refreshments & Networking**

Improving Logistical Efficiency, Safety & Navigating Quality Compliance Challenges in Radiopharmaceutical Facilities

Gokhan Cakmak
VP, Supply Chain & Logistics
Fusion Pharmaceuticals

11.45 **Navigating Regulatory & Logistical Complexities During Import/Export to Ensure Safe & Effective Delivery**

- Discuss the challenges of transporting radiopharmaceuticals, including adhering to import/export regulations for hazardous materials
- Examine how to coordinate with customs authorities to streamline the clearance process for radiopharmaceuticals
- Develop best practices to maintain the integrity of radiopharmaceuticals during transport to clinical sites and ensure efficacy

Conference Day Two
Thursday, September 26, 2024

Shankar Vallabhjosula
VP Radiopharmaceutical Sciences
Convergent Therapeutics

12.15 Aligning Compliance Standards in Multi-Product Facilities to Ensure Regulatory Approval

- Review challenges in maintaining regulatory compliance when manufacturing multiple radiopharmaceutical products in a single facility
- Develop best practices for achieving GMP compliance in multi-product facilities that handle complex production processes
- Discuss ways to integrate health and radiation safety protocols for smoother regulatory approvals

12.45 Roundtable Discussion: Build vs Buy: Navigating Facility Development Choices in Radiopharmaceutical Production

- Evaluate cost implications and operational efficiencies between constructing new facilities and acquiring existing ones
- Examine regulatory and compliance factors for building new facilities versus retrofitting existing ones
- Review case studies of strategic decisions and their outcomes in facility development

Michelle Hickey
SVP Global Supply Chain RLT
Telix Pharmaceuticals

Brett Miller
Senior Director, Global Supply Chain
Telix Pharmaceuticals

Matthew Hadden
Director of Health Physics
RayzeBio

D. Christian Parr
Vice President, Radiochemistry & Technical Operations
PharmaLogic

1.45 Lunch & Networking

Understanding the Diverse Development, Market Potential & Risk Management in Radiopharmaceutical Commercialization

Bryce Kanter
Senior Director Commercial Development
Clarity Pharmaceuticals

2.45 Translating a Reliable Manufacturing & Supply Chain Into Commercial Success

- Review the characteristics of radiopharmaceuticals that matter most for physicians and patients
- Discuss the commercial risks and opportunities of the different therapeutic isotopes (Cu-67, Ac-225, Pb-212, etc.)
- Explore the critical links between production and supply and the successful commercialization of radiopharmaceuticals

Erwin Bachmohr
Head of Procurement & Supply Chain
Ariceum Therapeutics

3.15 Developing Comprehensive Risk Assessment Models for Radiopharmaceutical Development

- Identify key regulatory, manufacturing, and distribution risks affecting the commercialization of radiopharmaceuticals
- Develop robust risk assessment frameworks that consider supply chain complexities, product quality, and regulatory compliance
- Review strategies to minimize clinical and market risks, including contingency planning and investment diversification

Kemp Dolliver
Director of Research
Brookline Capital Markets

3.45 Evaluating the Market Potential of New Radiopharmaceutical Therapies

- Assess the commercial viability of isotopes like copper-67, and lead-212
- Explore investment trends and venture capital funding in CDMOs to diversify product offerings
- Identify strategic partnerships and licensing opportunities to secure sustainable supply chains for new therapies

Brett Miller
Senior Director, Global Supply Chain
Telix Pharmaceuticals

4.15 Chair's Closing Remarks

4.30 End of Conference

2024 Confirmed Partners

Expertise Partner

CRB is a leading provider of sustainable engineering, architecture, construction and consulting solutions to the global life sciences and advanced technology industries. Our team provides best-in-class solutions that drive success and positive change for our clients, our people and our communities. CRB is a privately held company with a rich 40-year history of serving clients throughout the world, consistently striving for the highest standard of technical knowledge, creativity and execution.

www.crbusa.com

Expertise Partner

CAI strives to help our clients design, deliver, operate, and maintain quality, critical manufacturing (GMP related) or mission-critical facilities by pooling our global resources of over 800+ employees. Our engineering, technical, and consulting services encompass all aspects of operation: equipment, automation, process, and human performance. We integrate people, process, equipment, systems, and facilities into a high-performance manufacturing operation. The result is a superior level of operational performance and reliability. CAI is involved in each part of the project when you need to meet a higher standard.

www.cagents.com

Hosting Partner

PharmaLogic is a world-class contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other diseases. PharmaLogic has decades of expertise in drug development from discovery to commercialization through a top-tier network of radiopharmacies in North America. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefit of patients worldwide. For more information, visit:

www.radiopharmacy.com

Exhibition Partner

SHINE is a next-generation nuclear technology company, focused on deploying state-of-the-art fusion technology to help solve global problems and create a scalable path toward practical fusion energy. SHINE deploys its safe, cost-effective and environmentally friendly technology in a step-wise approach, beginning with our systems used for advanced industrial imaging in non-destructive testing of components used in aerospace, defense, transportation, energy and other sectors. SHINE's proprietary medical isotope production creates Molybdenum 99 and non-carrier added Lutetium 177 used in tens of thousands of daily procedures to diagnose and treat heart disease and late-stage cancer. For more information, follow SHINE on Facebook, LinkedIn and Twitter.

www.shinefusion.com

GET INVOLVED

Emma Schrod
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

2024 Confirmed Partners

Event Partner

NorthStar's Radiopharmaceutical CDMO/CMO unit offers customized services and expertise to accelerate biopharmaceutical companies' development and commercialization programs. The NorthStar CDMO is the first and only U.S. facility providing commercial-scale, multi-radioisotope production and radiopharmaceutical development on-site. With a 52,000 sq. ft. footprint, it sets new industry standards, serving the growing therapeutic and diagnostic radiopharmaceuticals market. Our facility effectively supports the entire product lifecycle, with cGMP and radiation safety programs to ensure high-quality and safe practices.

www.northstarnm.com

Event Partner

RLS (Radioisotope Life Sciences) Inc., the nation's only accredited nuclear pharmacy group, and the third-largest nuclear medicine pharmacy network in the United States, owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products. We endeavor to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of our commitment to quality, we provide tailored solutions and exceptional service to our more than 1500 customers.

www.rls.bio/

> "It was a great event, the right speakers for the topics"
>
> **Novartis**

GET INVOLVED

Emma Schrod
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us

2nd Annual Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit

September 24-26, 2024 | Boston, MA

The Only Industry Dedicated Platform to Foster New & Existing Relationships Within the Radiopharmaceutical Supply Chain & Manufacturing Landscape

With radiopharmaceuticals showing strong promise, cases like the **BMS-RayzeBio** phase III trial pausing highlights the detrimental impact that lack of robust radioisotope supply can have. The space needs more innovation, not only to support increasing radioisotope supplies, but to streamline drug product production and transport capabilities to keep trials running.

Uniting over **80+ TRP** leaders in **CMC, Supply Chain, QC, QA** and other leaders from drug developers, biotechs, established biopharma and large pharma. Our audience is actively seeking state-of-the-art companies to provide them with **raw radioisotopes, manufacturing support, supply chain logistics, facilities design and engineering, real estate** and much more.

If you understand their needs and have solutions that will effectively streamline their process development, don't miss your opportunity to leverage this platform to solidify existing partnerships and forge new ones.

Gain Market Insight:

As the only supply chain and manufacturing specific forum this is the place to stay ahead of the latest trends, innovations, and strategies.

Thought Leadership:

Grab the spotlight and present your work or participate in a panel discussion demonstrating your team's expertise and know-how.

Networking Opportunities:

Develop your position in the community by leveraging the numerous networking sessions at this highly focused summit.

Brand Visibility & Awareness:

Position your brand as a key innovation driver in front of an audience of radiopharmaceutical industry leaders and potential clients with your logo on event materials, our website, brochure, and signage.

New Business:

Gain access to the attendee list and interact in face-to-face conversations with a pool of the key players in the space.

Get the Edge on Competition:

Distinguish yourself from the crowd, displaying your innovative solutions and gain insights your competitors are missing.

SENIORITY OF ATTENDEES*

- Chief/CXO: 21%
- Director/Head: 38%
- President/VP: 24%
- Manager: 10%
- Professor: 3%
- Scientist: 4%

TYPES OF COMPANIES ATTENDING*



- Drug Developer
- Healthcare providers
- Hospitals
- Research Institute
- Consultant
- Equipment & Service Providers
- Construction
- Industrial Transportation
- Other

*Statistics Taken From Inagural TRP Supply Chain & Manufacturing Summit

GET INVOLVED

Emma Schrod
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

targeted-radiopharma-supplychain-manufacturing.com/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

Discover the pioneers paving the way for the future of radiopharmaceutical supply chain and manufacturing to stay ahead of the curve in this competitive market

Build your network and get face-to-face time with the industry experts and companies who have direct expertise in initiating clinical manufacturing capabilities

Troubleshoot and benchmark your processes and transform your supply chain capabilities to keep your trial running

Secure Your Place Now

Drug Developer Pricing*	Register & Pay By September 24 to Save!	On the Door Price
Full Package: Conference + Workshop Day	$4,097 **(Save $100)**	$4,197
Conference Only	$2,899 **(Save $100)**	$2,999

Solution Provider Pricing	Register & Pay By September 24 to Save!	On the Door Price
Full Package: Conference + Workshop Day	$4,997 **(Save $100)**	$5,097
Conference Only	$3,599 **(Save $100)**	$3,699

To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts**

- **10% discount – 3 Attendees**
- **15% discount – 4 Attendees**
- **20% discount – 5 + Attendees**

**Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Hilton Boston Logan Airport
One Hotel Dr, Boston, MA 02128, United States
www.hilton.com/en/hotels/boslhhh-hilton-boston-logan-airport/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom